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Type 2 diabetes mellitus (T2DM) is a complex progressive met-
abolic derangement associated with comorbidities such as 
obesity, dyslipidemia, and hypertension. Although a wide range 
of pharmacotherapies is available for T2DM, determining 
management strategies for T2DM that balance effectiveness, 
safety, and tolerability remains complex and challenging. 
  The prevalence of T2DM has increased rapidly in Asia, in-
cluding South Korea, over the past several decades [1]. The 
pathophysiologic mechanisms underlying T2DM in Asia are 
thought to be different from those in Western countries. In 
particular, pancreatic β-cell dysfunction may be important for 
the development of T2DM in certain Asian populations [2,3]. 
  Progressive β-cell failure, weight gain and hypoglycemia are 
the main side effects of sulfonylurea, one of the most common-
ly used antidiabetic agents. Long-term use of sulfonylurea can 
lead to the failure of monotherapy and ultimate dependence 
on insulin injections. Glucagon like peptide (GLP)-1 stimulates 
pancreatic β-cell differentiation and proliferation, and inhibits 
apoptosis [4]. Dipeptidyl peptide-4 (DPP-4) inhibitors enhance 
levels of active incretin hormones, gut-derived peptides that 
are released into the circulation after eating [5]. Sitagliptin is 
an oral, once-daily, potential, highly selective DPP-4 inhibitor. 
Numerous clinical studies of sitagliptin have been reported 
since the US Food and Drug Administration approved sita-
gliptin for monotherapy or combination therapy with metfor-
min or thiazolidinedione in 2006 [5-9]. According to a system-
ic review and meta-analysis, DPP-4 inhibitors lowered HbA1C 
by 0.74% (95% confidence interval [CI], 0.62% to 0.85%) com-
pared with placebo [10]. 
  Most studies indicate that sitagliptin treatment leads to sig-
nificant improvements in β-cell function. Given the important 
role that β-cell dysfunction plays in the progression of hyper-
glycemia, especially in Asian patients, sitagliptin treatment may 
be of particular therapeutic relevance for T2DM in Asian con-
texts. However, clinical studies of sitagliptin therapies in Asian 
or Korean diabetic patients are rare. A 2009 study found that 
18 week sitagliptin monotherapy was associated with signifi-
cantly improved glycemic control (mean HbA1c reduction, 
-1.0%) and was well tolerated by T2DM patients from China, 
India, and Korea [11]. According to this study, the reduction 
of HbA1C relative to placebo was greater in Korean and Indi-
an patients than in Chinese patients. The mean (95% CI) re-
ductions in HbA1C with sitagliptin treatment were -1.4% 
(-1.9% to -0.8%) in Korean patients, -1.4% (-1.7% to -1.0%) in 
Indian patients, and -0.7% (-0.9% to -0.5%) in Chinese patients. 
Furthermore, Korean patients showed the greatest reductions 
of fasting glucose and 2-hour postprandial glucose levels. How-
ever, the reasons for these differences were not elucidated, al-
though the authors suggested regional differences in environ-
ment, genetics, or adherence to study co-interventions such as 
diet and exercise. 
  Due to the current insufficiency of Asian or Korean data re-
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garding sitagliptin efficacy in patients with T2DM, the study 
by Kim et al. [12] is particularly relevant. In that study, young-
er, thinner diabetic patients were observed to have better ther-
apeutic results than older, heavier patients, suggesting that BMI 
and age should be considered before the selection of sitagliptin 
or other DPP-4 inhibitors for use in diabetic therapies. Treat-
ment response was defined as >10% HbA1c reduction or >20% 
fasting glucose reduction, and by this definition, the frequency 
of response in their sample was 81%. As many previous clini-
cal studies defined successful glucose-lowering effects accord-
ing to the number of patients with HbA1c <7%, additional 
studies are necessary to assess the therapeutic effects of sita-
gliptin and to identify clinical characteristics of patients that 
predict sitagliptin response.
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